CL2007002858A1 - Compuestos derivados de arilo-indol, inhibidores de la glicogeno sintasa quinasa-3-beta y/o moduladores de la actividad del canal n-metil-d-aspartato; formulacion farmaceutica, util para el tratamiento o prevencion de un desorden o trauma del snc, mi - Google Patents

Compuestos derivados de arilo-indol, inhibidores de la glicogeno sintasa quinasa-3-beta y/o moduladores de la actividad del canal n-metil-d-aspartato; formulacion farmaceutica, util para el tratamiento o prevencion de un desorden o trauma del snc, mi

Info

Publication number
CL2007002858A1
CL2007002858A1 CL200702858A CL2007002858A CL2007002858A1 CL 2007002858 A1 CL2007002858 A1 CL 2007002858A1 CL 200702858 A CL200702858 A CL 200702858A CL 2007002858 A CL2007002858 A CL 2007002858A CL 2007002858 A1 CL2007002858 A1 CL 2007002858A1
Authority
CL
Chile
Prior art keywords
glicogen
sintasa
quinasa
arilo
snc
Prior art date
Application number
CL200702858A
Other languages
English (en)
Inventor
Moshe Peleg-Shulman Tal Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of CL2007002858A1 publication Critical patent/CL2007002858A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL200702858A 2006-10-03 2007-10-03 Compuestos derivados de arilo-indol, inhibidores de la glicogeno sintasa quinasa-3-beta y/o moduladores de la actividad del canal n-metil-d-aspartato; formulacion farmaceutica, util para el tratamiento o prevencion de un desorden o trauma del snc, mi CL2007002858A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84864206P 2006-10-03 2006-10-03

Publications (1)

Publication Number Publication Date
CL2007002858A1 true CL2007002858A1 (es) 2008-05-16

Family

ID=39271279

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702858A CL2007002858A1 (es) 2006-10-03 2007-10-03 Compuestos derivados de arilo-indol, inhibidores de la glicogeno sintasa quinasa-3-beta y/o moduladores de la actividad del canal n-metil-d-aspartato; formulacion farmaceutica, util para el tratamiento o prevencion de un desorden o trauma del snc, mi

Country Status (14)

Country Link
US (3) US7622495B2 (es)
EP (2) EP2086932B1 (es)
JP (1) JP5426386B2 (es)
CN (1) CN101528689B (es)
AR (1) AR063128A1 (es)
CL (1) CL2007002858A1 (es)
DK (1) DK2086932T3 (es)
ES (1) ES2523026T3 (es)
HK (1) HK1133886A1 (es)
PL (1) PL2086932T3 (es)
PT (1) PT2086932E (es)
SI (1) SI2086932T1 (es)
TW (1) TWI407954B (es)
WO (1) WO2008041140A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535336A1 (en) 2006-10-21 2012-12-19 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
MX2010013393A (es) 2008-06-06 2011-06-21 Pharma Two B Ltd Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP2014503528A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2013152039A1 (en) * 2012-04-02 2013-10-10 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
US9834801B2 (en) * 2013-03-14 2017-12-05 Vistagen Therapeutics, Inc. Methods for the synthesis of chiral kynurenine compounds
WO2016027757A1 (ja) * 2014-08-18 2016-02-25 国立大学法人大阪大学 新規２－アミノベンゾイル誘導体
BR112017013193B1 (pt) * 2014-12-19 2023-10-03 Glaxosmithkline Intellectual Property Development Limited Composto inibidor de kmo, composição farmacêutica que compreende o dito composto, bem como uso terapêutico do mesmo
AR108586A1 (es) * 2016-06-10 2018-09-05 Lilly Co Eli Compuestos de 2,3-dihidro-1h-indol
CN106362155A (zh) * 2016-10-08 2017-02-01 无锡汉强医药科技有限公司 Gsk3抑制剂在制备治疗尼曼匹克病c型疾病中的应用
CN106995828B (zh) * 2017-02-04 2020-10-09 中国科学院成都生物研究所 利用喜树悬浮细胞生产n1-乙酰犬尿胺的方法
JPWO2018216705A1 (ja) * 2017-05-23 2020-03-26 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
WO2019178013A1 (en) * 2018-03-14 2019-09-19 Albert Einstein College Of Medicine Immunoregulatory role of 3-oh-kynurenamine and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870162A (en) * 1954-04-28 1959-01-20 Upjohn Co Production of certain tryptamines and compounds produced in the process
JPS5336455B2 (es) 1973-02-03 1978-10-03
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
JP2000007626A (ja) 1998-06-25 2000-01-11 Taisho Pharmaceut Co Ltd Ｎ−置換ニトロアニリン誘導体
IL138825A (en) 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
RU2004113111A (ru) * 2001-09-27 2005-06-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индола в качестве ингибиторов сох 11
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
IL156669A0 (en) 2003-06-26 2004-01-04 Neurim Pharma 1991 2-aminobenzoyl derivatives
DK1809622T3 (da) 2004-09-22 2010-11-08 Janssen Pharmaceutica Nv Inhibitorer af interaktionen mellem MDM2 og P53

Also Published As

Publication number Publication date
HK1133886A1 (en) 2010-04-09
ES2523026T3 (es) 2014-11-20
SI2086932T1 (sl) 2014-12-31
EP2086932B1 (en) 2014-08-27
WO2008041140A8 (en) 2009-07-09
US20080132559A1 (en) 2008-06-05
JP5426386B2 (ja) 2014-02-26
WO2008041140A2 (en) 2008-04-10
EP2664615A1 (en) 2013-11-20
CN101528689A (zh) 2009-09-09
US8003702B2 (en) 2011-08-23
PL2086932T3 (pl) 2015-02-27
US8236858B2 (en) 2012-08-07
PT2086932E (pt) 2014-11-10
DK2086932T3 (da) 2014-11-10
TW200824684A (en) 2008-06-16
TWI407954B (zh) 2013-09-11
JP2010505816A (ja) 2010-02-25
AR063128A1 (es) 2008-12-30
US7622495B2 (en) 2009-11-24
WO2008041140A3 (en) 2008-08-14
CN101528689B (zh) 2013-04-24
US20100048663A1 (en) 2010-02-25
EP2086932A2 (en) 2009-08-12
US20110319494A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
CL2007002858A1 (es) Compuestos derivados de arilo-indol, inhibidores de la glicogeno sintasa quinasa-3-beta y/o moduladores de la actividad del canal n-metil-d-aspartato; formulacion farmaceutica, util para el tratamiento o prevencion de un desorden o trauma del snc, mi
PH12017501306A1 (en) Inhibitors of histone demethylases
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
WO2010027875A3 (en) Compounds that modulate intracellular calcium
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2009035818A8 (en) Compounds that modulate intracellular calcium
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
WO2011139489A3 (en) Compounds that modulate intracellular calcium
SG169997A1 (en) Catheter cleaning devices
WO2009076454A3 (en) Compounds that modulate intracellular calcium
WO2010021693A3 (en) Mif modulators
WO2011140202A3 (en) Mif modulators
BR112014030386A2 (pt) compostos e composições para modular a atividade de egfr
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IL211825A (en) Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention
CL2007003557A1 (es) Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2012027710A3 (en) Compounds that modulate intracellular calcium
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
WO2010034011A3 (en) Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release
WO2011139765A3 (en) Compounds that modulate intracellular calcium